Inovalon — Q2 2016 Earnings Presentation
22 slides from Inovalon's earnings presentation, Aug 3, 2016
Slide 1: Note Regarding Forward-Looking Statements
Note Regarding Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including, but not limited to, statements regarding future results of the operations and financial position of Ino
Slide 2: Introduction
Introduction The contents of this presentation are supplemental to the earnings release dated August 3, 2016 to provide shareholders additional insight into the Company’s performance, expectations. plans and Presented within this deck are materials that describe: • • • Metrics regarding performance
Slide 3: Expanding Proprietary Datasets
Expanding Proprietary Datasets As of June 30th, 2016, Inovalon’s proprietary datasets continued to materially expand, growing to contain data pertaining to more than: • • 804,000 physicians 306,000 clinical facilities • • 137 million unique patients 11.7 billion medical events MORE2 REGISTRY® GROWTH
Slide 4: Expanding Patient Analytical Months (PAM)
Expanding Patient Analytical Months (PAM) As of June 30th, 2016, Inovalon’s Patient Analytical Months (PAM) metric, which tracks the number of analytical processes that the Company runs on patients, continued to show strong growth, increasing to approximately 24.3 billion. The Company sees PAM as a
Slide 5: Full Year 2016 Revised Revenue Guidance
Full Year 2016 Revised Revenue Guidance Revenue Growth Drivers As a result of our investment in an enhanced sales organization and advanced sales tools our sales pipeline is the largest it has ever been and is in excess of twice the size it was at the beginning of the year. We continue to innovate a
Slide 6: Seasonality Trends – Revenue
Seasonality Trends – Revenue Inovalon had previously expected seasonality trends experienced over recent years to continue in 2016, shifting a higher percentage of our annual revenue from the first half of the year into the second half of the year. However, due to the previously described factors of
Slide 7: Continuous Enhancement & Platform Innovation I
Continuous Enhancement & Platform Innovation I An example of platform capabilities which Inovalon has advanced in their sophistication repeatedly over the years, QSI-XL™, Inovalon’s clinical quality outcomes analytics platform, was further enhanced during the second quarter of 2016. A fully cloud-ac
Slide 8: Continuous Enhancement & Platform Innovation II
Continuous Enhancement & Platform Innovation II Not all platform capabilities have been advanced in their cloud-sophistication as rapidly as others. During the quarter, one of the Company’s long-standing platform capabilities, CARA®, a retrospective risk score accuracy platform, experienced an accel
Slide 9: Continuous Enhancement & Platform Innovation III
Continuous Enhancement & Platform Innovation III The development of CCA QSI-XL™, continued enhancement of Data Diagnostics™, and the acceleration of CCA CARA®, join the ranks of a number of additional technology advancements which are being applied to Inovalon’s platform. These are resulting in the
Slide 10: Significant Cloud Capability Expansion
Significant Cloud Capability Expansion Active, Active, Active During Q2 2016, we initiated investments in significant core platform capabilities to allow for dynamic storage and compute capacity provisioning, scaling and load balancing across various clouds and the creation of additional large-scale
Slide 11: New Technology Expansions: QSI-XL
New Technology Expansions QSI-XL™ Cloud-based big-data clinical quality analytics platform 10,000,000 Patients Able to process nation’s largest patient populations of 50M+ Game-changing processing speeds • • 5,000,000 Patients 2,000,000 Patients 1,000,000 Patients 500,000 Patients 50,000 Patients Pe
Slide 12: New Technology Expansions: OCR & Natural Language Processing
New Technology Expansions OCR & Natural Language Processing Cloud-based unstructured data analysis Able to dramatically accelerate processing times and client value Game-changing capacity and efficiency improvements • • INOV Q2 2016 Earnings Presentation Supplement (8.3.16) v1.0.0 13 © 2016 by Inova
Slide 13: New Technology Expansions: Post-Acute Care (PAC) Platform
New Technology Expansions Post-Acute Care (PAC) Platform Inovalon’s PAC Solution Platform brings together a unique combination of data, interconnectivity, analytics, and clinical landscape intervention capabilities to allow clients to gain the necessary insight to better determine and manage PAC pat
Slide 14: New Technology Expansions: INDICES Advanced Data Visualization
New Technology Expansions INDICES® Advanced Data Visualization Client Access INOV Q2 2016 Earnings Presentation Supplement (8.3.16) v1.0.0 15 © 2016 by Inovalon. All rights reserved.
Slide 15: New Technology Expansions: Data Diagnostics
New Technology Expansions Data Diagnostics™ Bringing on-demand, real-time analytics to the point of care 1 Reaching more than half of the physicians in the U.S. • • 2 1.2 billion clinical encounters per year opportunity 1: As provided by Quest Diagnostics; 2: Centers for Disease Control and Preventi
Slide 16: New Technology Expansions: Interoperability Platform
New Technology Expansions Interoperability Platform Inovalon’s bi-directional Interoperability Platform enables automation for clinical data abstraction, normalization and analytic processes. The convergence of traditional claims, end-to-end data connectivity and process exchange which seamlessly in
Slide 17: New Technology Expansions: Pharma/Life Sciences Stack
New Technology Expansions Pharma/Life Sciences Stack Inovalon has introduced a “Pharma & Life Sciences Stack” of capabilities consisting of a combination of Avalere’s subject matter expertise and Inovalon’s technology and data platforms. The combination is being offered in a way that provides what i
Slide 18: Why is Gross Margin Percentage Changing?
Why is Gross Margin Percentage Changing? Year-over-year gross margin profit drivers are being influenced by the following forces: revenue mix driven by variations in client demand, pricing strategy in new and transitional platform capabilities, and platform efficiency gains. The resulting impact of
Slide 19: Why is Adjusted EBITDA Margin Changing?
Why is Adjusted EBITDA Margin Changing? Year-over-year profit drivers are being influenced by a number of forces in 2016. In addition to those forces impacting the Gross Margin (as discussed on Slide 19), investments in platform capabilities, technologies and corporate infrastructure are also having
Slide 20: Balance Sheet & Cash Flow
Balance Sheet & Cash Flow Balance Sheet Highlights Cash, Cash Equivalents, and Short-Term Investments Accounts Receivable Credit Facilities and Capital Lease Obligations(1) Stockholders' Equity $ $ $ $ 743,883 94,772 274,130 769,813 $ $ $ $ 728,164 81,305 281,655 739,156 Cash Flow Highlights Net Cas
Slide 21: Balance Sheet & Cash Flow
Balance Sheet & Cash Flow inovalon po sof (In thousands) ‘June 30,2016 December 31, 2015 Balance Sheet Highlights Cash, Cash Equivalents, and Short-Term Investments 743,883 728,164 Credit Facilities and Capital Lease Obligations” Stockholders’ Equity \(n thousands) Cash Flow Highlights Net Cash Prov
Slide 22: RY Woe
RY Woe Wily, Any inovalon hcare empowered